Table 5 |
||||||||
|
Trials testing lysine |
||||||||
|
Reference |
Study Design |
Sample Population |
Intervention |
Control |
Length of Treatment |
Outcomes |
Direction of Evidence |
Reported Adverse Events |
|
|
||||||||
|
Jezova (2005) [67] |
Randomized; Double-blind; Parallel Group |
29 healthy male subjects at the upper limit of the normal range of a trait anxiety scale1 |
Mixture of L-lysine and L-arginine (3 g each/day) |
Placebo |
10 days |
AMino acid treatment enhanced adrenocorticotropic hormone, cortisol, adrenaline and noradrenaline levels and galvanic skin responses during stress; no effect on heart rate and blood pressure. |
+ |
None |
|
|
||||||||
|
Smriga (2007) [68] |
Randomized; Double-blind; Parallel Group |
108 healthy Japanese adults |
Oral L-lysine (2.64 g/day) and L-arginine (2.64 g/day) |
Placebo |
1 week |
L-lysine/L-arginine treatment significantly reduced trait and state anxiety; also decreased basal levels of salivary cortisol and chromogranin-A in male subjects |
+ |
None |
|
|
||||||||
|
STAI: State Trait Anxiety Inventory. 1. Scored above 45 on STAI questionnaire. |
||||||||
|
Lakhan and Vieira Nutrition Journal 2010 9:42 doi:10.1186/1475-2891-9-42 |
||||||||